STAGE IIIC LUNG CANCER AJCC V8

This early-phase trial is testing whether combining two drugs—brigatinib and bevacizumab—can help people with a specific kind of lung cancer (ALK-positive non-small cell lung cancer) whose cancer has gotten worse despite previous ALK-targeted therapy. The study involves just 5 pa…

This early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for patients with stage II or III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this chemo-free app…

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This study tests whether adding an experimental drug (N-803) to the immunotherapy pembrolizumab can help control advanced non-small cell lung cancer better than standard treatments. The drug combo aims to activate natural killer cells and boost the immune system's attack on cance…

This phase I/II trial is testing whether adding the CIMAvax vaccine (which targets a growth factor that tumors need) to standard immunotherapy drugs (nivolumab or pembrolizumab) can better control advanced non-small cell lung cancer and squamous head/neck cancer. The study involv…

This early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that has stopped responding to standard immunotherapy. The treatment uses immune cells from umbilical cord blood that are genetically modified to better recognize and attack cancer ce…

This study tests a combination of two drugs—pembrolizumab (an immunotherapy) and trametinib (a targeted therapy)—in people with advanced non-small cell lung cancer that has come back or spread. The goal is to see if the combination is safe and can shrink or control tumors. Partic…

This early-phase study tests the safety and best dose of a new drug, minnelide, when given with the standard drug osimertinib for people with advanced EGFR-mutated non-small cell lung cancer. The trial enrolls about 8 adults whose cancer has spread or cannot be removed by surgery…

This early-stage study tests a drug called NBTXR3, which makes cancer cells more sensitive to radiation, combined with a second round of radiation for people whose non-small cell lung cancer has returned and cannot be surgically removed. The main goal is to find the safest dose a…

This study compares two treatments for lung lesions in people with non-small cell lung cancer, sarcoma, or colorectal cancer that has spread. One treatment uses microwaves to heat and kill tumor cells, while the other is a surgery to remove a small piece of lung. Researchers want…

This study tests two treatment plans for people with advanced non-squamous non-small cell lung cancer. One group gets immunotherapy (pembrolizumab) alone first, then chemo plus or minus immunotherapy later. The other group gets immunotherapy plus chemo from the start, followed by…

This study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation, and continuing it afterward, helps people with stage III lung cancer that cannot be surgically removed live longer and keep the cancer from coming back. About 660 adults with newly diagn…

This study tests whether a lung cancer drug called atezolizumab can be safely given as a shot under the skin at home, with doctors monitoring patients through video calls. It involves 5 adults with non-small cell lung cancer. The goal is to see if this home-based approach is prac…

This early-phase study tests a new drug combination for people with advanced ALK-positive non-small cell lung cancer. The goal is to find the best dose of ensartinib when given with standard chemotherapy and a targeted antibody. About 12 participants will receive the treatment to…

This study tests two drugs together for people with small cell lung cancer or other high-grade neuroendocrine cancers that have already been treated. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the immune system attack the tumor. The goal is to …

This study looks at whether adding radiation therapy to standard immunotherapy (with or without chemo) helps people with advanced non-small cell lung cancer that lacks the PD-L1 marker. About 427 adults with stage IIIB, IIIC, or IV cancer will be randomly assigned to get either t…

This study tests an online program called BREATHE for women with non-small cell lung cancer. The program uses mindfulness, compassion, and emotional processing to help improve social well-being and reduce distress. About 70 women will participate, and the main goal is to see if t…

This phase III trial is testing whether a telehealth self-management program can improve care coordination and quality of life for survivors of non-small cell lung cancer or colorectal cancer. About 403 participants who finished treatment 4 months ago will receive coaching sessio…

This study looks at whether a drug called anamorelin can help improve appetite and stop weight loss in people with advanced lung cancer who have lost their appetite and are losing weight. About 25 participants will take either the drug or a placebo and share their experiences thr…

This study looks at whether updating radiation treatment plans at set times (adaptive planning) can lower side effects like lung inflammation in people with stage II-IV non-small cell lung cancer. About 34 participants will receive standard radiation and immunotherapy, but their …

This study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer cope with fears about their future. About 42 participants will try the program, which includes sessions and home activities. The goal is to see if the program is practical and he…

This early-stage study tests whether giving a single, very focused dose of radiation after lung cancer surgery is safe and causes fewer side effects than standard weeks-long radiation. It involves 50 adults with non-small cell lung cancer who had surgery but still have cancer cel…

This study aims to find out why some cancer patients develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track over 1,300 people with breast, lung, or ovarian cancer to see how age, gender, and other factors affect their risk. …